|
|
|
|
===Diabetes===
Given the evidence for chromium deficiency causing problems with glucose management in the context of intravenous nutrition products formulated without chromium,<ref name=Stehle2016>{{cite journal |vauthors=Stehle P, Stoffel-Wagner B, Kuhn KS |title=Parenteral trace element provision: recent clinical research and practical conclusions |journal=Eur J Clin Nutr |volume=70 |issue=8 |pages=886–893 |date=2016 |pmid=27049031 |pmc=5399133 |doi=10.1038/ejcn.2016.53 |url=}}</ref> research interest turned to whether chromium supplementation for people who have type 2 diabetes but are not chromium deficient could benefit. Looking at the results from four meta-analyses, one reported a statistically significant decrease in fasting [[plasma glucose]] levels (FPG) and a non-significant trend in lower [[Glycated hemoglobin|hemoglobin A1C]] (HbA1C).<ref name=Mauro2016>{{cite journal |vauthors=San Mauro-Martin I, Ruiz-León AM, et al.|title=[Chromium supplementation in patients with type 2 diabetes and high risk of type 2 diabetes: a meta-analysis of randomized controlled trials] |language=Spanish; Castilian |journal=Nutr Hosp |volume=33 |issue=1 |pages=27 |date=2016 |pmid=27019254 |doi=10.20960/nh.v33i1.27 |url=}}</ref> A second reported the same,<ref name=Abdoll2013>{{cite journal |vauthors=Abdollahi M, Farshchi A, Nikfar S, Seyedifar M |title=Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials |journal=J Pharm Pharm Sci |volume=16 |issue=1 |pages=99–114 |date=2013 |pmid=23683609 |doi= |url=}}</ref>, a third reported significant decreases for both measures,<ref name=Suk2014>{{cite journal |vauthors=Suksomboon N, Poolsup N, Yuwanakorn A |title=Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes |journal=J Clin Pharm Ther |volume=39 |issue=3 |pages=292–306 |date=2014 |pmid=24635480 |doi=10.1111/jcpt.12147 |url=}}</ref> while a fourth reported no benefit for either.<ref>{{cite journal |vauthors=Bailey CH |title=Improved meta-analytic methods show no effect of chromium supplements on fasting glucose |journal=Biol Trace Elem Res |volume=157 |issue=1 |pages=1–8 |date=January 2014 |pmid=24293356 |doi=10.1007/s12011-013-9863-9 |url=}}</ref> A review published in 2016 listed 53 [[randomized clinical trial]]s that were included in one or more of six [[meta-analysis|meta-analyses]]. It concluded that whereas there may be modest decreases in FPG and/or HbA1C that achieve statistical significance in some of these meta-analyses, few of the trials achieved decreases large enough to be expected to be relevant to clinical outcome. The authors also mentioned that trial design was for chromium as an addition to standard glycemic control medications, and so did not evaluate chromium as a first treatment for type 2 diabetes, or for prevention of progression from pre-diabetes to diabetes. The conclusion was that "...there is still little reason to recommend chromium dietary supplements to achieve clinically meaningful improvements in glycemic control."<ref name=Costello2016>{{cite journal |vauthors=Costello RB, Dwyer JT, Bailey RL |title=Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness |journal=Nutr. Rev. |volume=74 |issue=7 |pages=455–468 |date=2016 |pmid=27261273 |doi=10.1093/nutrit/nuw011 |url=}}</ref> The American Diabetes Association publishes a standards of care review every year. The 2018 review makes no mention of chromium supplementation as a possible treatment.<ref>[https://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf Standards of Medical Care for Diabetes - 2018] Diabetes Care 2008:41:Supplement 1.</ref>
====Government-approved health claims====
|
